Strategic acquisition Adverum Biotechnologies is being acquired by Eli Lilly as of October 2025, signaling potential continuity of ongoing programs and possible integration of its IVT gene therapy platform into Lilly's ophthalmology portfolio. This presents opportunities to engage Lilly’s enterprise sales, post-merger integration teams, and remaining collaborators for infrastructure, data services, and continuation of clinical services.

One-time therapy The company aims to deliver durable, single-administration intravitreal gene therapies, which can shift customers toward fewer injections and simpler treatment regimens. This creates sales potential for partners offering manufacturing scalability, in-office delivery support, and payer/reimbursement navigation tied to reduced treatment burden.

Ophthalmology focus Target diseases include wet age-related macular degeneration and other sight-threatening ocular diseases. Opportunities exist to cross-sell related ophthalmology research services, companion diagnostics, clinical trial services, and collaboration on real-world evidence collection to support product adoption.

Clinical-stage potential As a clinical-stage gene therapy company with a proprietary IVT platform, there is demand for CRO/PMO partnerships, regulatory strategy support, and manufacturing scale-up services to prepare for potential Phase 3 milestones, filings, and market launch readiness.

Financial and partnership signals Revenue footprint is modest with substantial funding and a trajectory aligned to pivotal clinical milestones. This suggests openings for strategic partnerships, joint ventures, or co-development discussions with larger biopharma players seeking to enrich their ocular gene therapy pipelines and accelerate time to value.